Results 271 to 280 of about 65,011 (307)
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade. [PDF]
J Immunother Cancereuropepmc +1 more source
Alpha-2 agonists for refractory neurological symptoms in pediatric palliative care: a scoping review. [PDF]
Front PediatrSalerno A +5 more
europepmc +1 more source
Optimal Effect-Site Concentration of Propofol for Hemodynamic Stability During Intubation with Dexmedetomidine: A Randomized Controlled Study. [PDF]
Drug Des Devel TherGao H +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
BMJ Supportive & Palliative Care, 2020
Dexmedetomidine is a selective α2-adrenoreceptor agonist with a broad range of effects, including easily controllable sedation, analgesia and anxiolysis. Because of these favorable features, it has replaced traditional sedatives, such as benzodiazepines, and is becoming the first-line sedative for the patients in intensive care units.
Akiko Mano +8 more
openaire +3 more sources
Dexmedetomidine is a selective α2-adrenoreceptor agonist with a broad range of effects, including easily controllable sedation, analgesia and anxiolysis. Because of these favorable features, it has replaced traditional sedatives, such as benzodiazepines, and is becoming the first-line sedative for the patients in intensive care units.
Akiko Mano +8 more
openaire +3 more sources
Der Anaesthesist, 2013
Dexmedetomidine is a highly selective α2-receptor agonist with sedative, analgetic and anxiolytic effects. It is chemically related to clonidine and has been an authorized drug in Europe since September 2011. Dexmedetomidine enables a level of sedation in which mechanically ventilated patients may be woken by verbal stimulation (Richmond agitation ...
G. Gerresheim, U. Schwemmer
openaire +3 more sources
Dexmedetomidine is a highly selective α2-receptor agonist with sedative, analgetic and anxiolytic effects. It is chemically related to clonidine and has been an authorized drug in Europe since September 2011. Dexmedetomidine enables a level of sedation in which mechanically ventilated patients may be woken by verbal stimulation (Richmond agitation ...
G. Gerresheim, U. Schwemmer
openaire +3 more sources
Drugs, 2000
Dexmedetomidine is a potent alpha2-adrenoceptor agonist with 8 times higher affinity for the alpha2-adrenoceptor than clonidine. Dexmedetomidine has shown sedative, analgesic and anxiolytic effects after intravenous administration to healthy volunteers or postsurgical patients in the intensive care unit.
Karen L. Goa +2 more
openaire +3 more sources
Dexmedetomidine is a potent alpha2-adrenoceptor agonist with 8 times higher affinity for the alpha2-adrenoceptor than clonidine. Dexmedetomidine has shown sedative, analgesic and anxiolytic effects after intravenous administration to healthy volunteers or postsurgical patients in the intensive care unit.
Karen L. Goa +2 more
openaire +3 more sources
Current Opinion in Critical Care, 2001
Effective use of sedative-hypnotic and analgesic agents is an integral part of providing patient comfort and safety. Of the numerous drugs administered, benzodiazepines, propofol, and narcotics are the most popular. Even these proven, time-tested sedative-hypnotics and analgesics are not perfect, however, and modern intensive care demands a more ideal ...
D B, Coursin +2 more
openaire +2 more sources
Effective use of sedative-hypnotic and analgesic agents is an integral part of providing patient comfort and safety. Of the numerous drugs administered, benzodiazepines, propofol, and narcotics are the most popular. Even these proven, time-tested sedative-hypnotics and analgesics are not perfect, however, and modern intensive care demands a more ideal ...
D B, Coursin +2 more
openaire +2 more sources